AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2679269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized verbal instruction alone
Number of subjects: 100
Study 2679269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized verbal instruction plus an automatic visual signal during inspiration
Number of subjects: 100
Study 2679269 — intervention group
Group type: COMPARATOR
Intervention: Both treatment protocols
Number of subjects: 100
Study 388168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg daily
Number of subjects: 48
Study 388168 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 48
Study 30709384 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support services
Number of subjects: 349
Study 28182535 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 0
Study 28182535 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressing (SSD)
Number of subjects: 0
Study 28182535 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis of treatment groups
Number of subjects: 0
Study 26540907 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory vibrating device
Number of subjects: 39
Study 26540907 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (control group)
Number of subjects: 39
Study 23627345 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mononuclear cell depletion by leukapheresis
Number of subjects: 30
Study 23627345 — intervention group
Group type: COMPARATOR
Intervention: Sham leukapheresis
Number of subjects: 30
Study 21801977 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure (AOBP)
Number of subjects: 101
Study 21801977 — intervention group
Group type: EXPERIMENTAL
Intervention: Office Mercury Sphygmomanometer
Number of subjects: 101
Study 21801977 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour Ambulatory Blood Pressure Monitor (ABPM)
Number of subjects: 101
Study 21801977 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime Ambulatory Blood Pressure Monitor (ABPM)
Number of subjects: 101
Study 21801977 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Self-Measurement
Number of subjects: 101
Study 21801977 — intervention group
Group type: COMPARATOR
Intervention: Comparison of office methods vs ambulatory methods
Number of subjects: 101
Study 21801977 — intervention group
Group type: COMPARATOR
Intervention: Achievement of therapeutic goals
Number of subjects: 101
Study 19255407 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg IV once every 4 weeks plus GA 20 mg subcutaneously once daily for ≤ 20 weeks
Number of subjects: 110
Study 19255407 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate (GA) alone
Number of subjects: 110
Study 19255407 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab + GA
Number of subjects: 110
Study 18575843 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartCare/PS
Number of subjects: 102
Study 18575843 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study 18575843 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartCare/PS (adjusted)
Number of subjects: 102
Study 18575843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 15196161 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, lidocaine and epinephrine mixture (5-FU + LE)
Number of subjects: 76
Study 15196161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (serum saline injection)
Number of subjects: 76
Study 11772799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.3 mg/kg orally 1 h before surgery and placebo 6 h later (Group C1)
Number of subjects: 96
Study 11772799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride before and after surgery (Group C2)
Number of subjects: 96
Study 11772799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 96
Study 9763159 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent smoking (defined as smoking before age 18)
Number of subjects: 1042
Study 9763159 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent smoking
Number of subjects: 1042
Study 8087821 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg TNTG applied for 16 h with a 'nitrate‐free' interval of 8 h
Number of subjects: 129
Study 8087821 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg TNTG applied for 16 h followed by a 'nitrate‐low' interval of 5 mg applied for 8 h
Number of subjects: 129
Study 2587133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 (10 mg intramuscularly, repeated if delivery did not occur in 4 days, followed by 20 mg orally daily until the end of the 34th week if pregnancy continued)
Number of subjects: 98
Study 2587133 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 98
Study 782504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Ciclopirox solution
Number of subjects: 93
Study 782504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 15208931 — intervention group
Group type: EXPERIMENTAL
Intervention: E + AA + PA
Number of subjects: 60
Study 15208931 — intervention group
Group type: EXPERIMENTAL
Intervention: E + PA
Number of subjects: 60
Study 15208931 — intervention group
Group type: EXPERIMENTAL
Intervention: D + PA
Number of subjects: 60
Study 15208931 — intervention group
Group type: EXPERIMENTAL
Intervention: D + AA + PA
Number of subjects: 60
Study 15208931 — intervention group
Group type: EXPERIMENTAL
Intervention: D + AA
Number of subjects: 60
Study 15208931 — intervention group
Group type: EXPERIMENTAL
Intervention: E + AA
Number of subjects: 60
Study 30477705 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Program (EP)
Number of subjects: 60
Study 30477705 — intervention group
Group type: COMPARATOR
Intervention: Fitness Trackers (FT)
Number of subjects: 60
Study 29127060 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study 29127060 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (lenograstim) 15 μg/kg for 5 days
Number of subjects: 81
Study 29127060 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF for 5 days followed by leukapheresis and intravenous infusion of CD133-positive stem cells (0.2 × 10^6 cells per kg per infusion)
Number of subjects: 81
Study 26456672 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbid mononitrate 20 mg tablet once daily applied vaginally until delivery
Number of subjects: 300
Study 26456672 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal tablets
Number of subjects: 300
Study 23583234 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/day of alpha-tocopherol
Number of subjects: 613
Study 23583234 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day memantine
Number of subjects: 613
Study 23583234 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/day alpha-tocopherol plus 20 mg/day memantine
Number of subjects: 613
Study 23583234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 22360820 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg (RSV40)
Number of subjects: 825
Study 22360820 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg (RSV20)
Number of subjects: 825
Study 22360820 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 80 mg (ATV80)
Number of subjects: 825
Study 20820832 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC207 (novel agent)
Number of subjects: 0
Study 20820832 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid
Number of subjects: 0
Study 20820832 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 0
Study 17588187 — intervention group
Group type: EXPERIMENTAL
Intervention: AT nerve block with LA (Bupivacaine, 2.5 mg/ml)
Number of subjects: 28
Study 17588187 — intervention group
Group type: EXPERIMENTAL
Intervention: IA injection with LA (Bupivacaine, 2.5 mg/ml)
Number of subjects: 28
Study 17588187 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (isotonic saline)
Number of subjects: 28
Study 16307966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice daily for 10 days)
Number of subjects: 100
Study 16307966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16307966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 100
Study 12212873 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized injection device (Wand)
Number of subjects: 40
Study 12212873 — intervention group
Group type: COMPARATOR
Intervention: Traditional anesthetic delivery system
Number of subjects: 40
Study 9466020 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin and protamine management (Group 1)
Number of subjects: 135
Study 9466020 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and protamine by in vitro titration (Group 2)
Number of subjects: 135
Study 9466020 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin dose titrated (Group 3)
Number of subjects: 135
Study 9466020 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine dose titrated (Group 4)
Number of subjects: 135
Study 9097747 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TIA and abnormal iris transluminance
Number of subjects: 46
Study 9097747 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects without transluminance
Number of subjects: 46
Study 9097747 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TIA with positive iris transluminance
Number of subjects: 46
Study 9097747 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TIA with abnormal iris transluminance
Number of subjects: 46
Study 2497830 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet given to patients at discharge (65 patients)
Number of subjects: 131
Study 2497830 — intervention group
Group type: COMPARATOR
Intervention: Control group (66 patients)
Number of subjects: 131
Study 2497830 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet group (65 patients)
Number of subjects: 131
Study 777074 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.22 mg of tartrazine
Number of subjects: 38
Study 777074 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 31866161 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping® Group (n=21)
Number of subjects: 63
Study 31866161 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group (normal surgical tape) (n=21)
Number of subjects: 63
Study 31866161 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control Group (n=21)
Number of subjects: 63
Study 31866161 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 63
Study 30683591 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole and Clomiphene Citrate (CC) - 2.5 mg letrozole and 50 mg CC daily on cycle days 3–7 for one treatment cycle
Number of subjects: 70
Study 30683591 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone - 2.5 mg letrozole daily on cycle days 3–7 for one treatment cycle
Number of subjects: 70
Study 28267466 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multi-domain physical rehabilitation intervention
Number of subjects: 360
Study 28267466 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 360
Study 28267466 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 360
Study 27143274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP <140 mm Hg)
Number of subjects: 2839
Study 27143274 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering (target SBP <180 mm Hg)
Number of subjects: 2839
Study 24411490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bofutsushosan with probiotics
Number of subjects: 0
Study 24411490 — intervention group
Group type: COMPARATOR
Intervention: Bofutsushosan with placebo
Number of subjects: 0
Study 22259078 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light exposure
Number of subjects: 10
Study 22259078 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light exposure
Number of subjects: 10
Study 19370427 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pretreatment megavoltage computed tomography (MVCT)
Number of subjects: 10
Study 19370427 — intervention group
Group type: COMPARATOR
Intervention: Simulated bone alignment
Number of subjects: 10
Study 19370427 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily MVCT
Number of subjects: 10
Study 17184429 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol anesthesia
Number of subjects: 39
Study 17184429 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-fentanyl anesthesia
Number of subjects: 39
Study 14607494 — intervention group
Group type: EXPERIMENTAL
Intervention: RANKL protein levels in peri-implant tissues of patients with implant failure
Number of subjects: 0
Study 14607494 — intervention group
Group type: EXPERIMENTAL
Intervention: OPG protein levels in peri-implant tissues
Number of subjects: 0
Study 14607494 — intervention group
Group type: EXPERIMENTAL
Intervention: RANK mRNA expression in cells containing wear particles
Number of subjects: 0
Study 14607494 — intervention group
Group type: EXPERIMENTAL
Intervention: RANKL mRNA expression in peri-implant tissues
Number of subjects: 0
Study 11303975 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate 900 mg/day
Number of subjects: 388
Study 11303975 — intervention group
Group type: COMPARATOR
Intervention: Gabexate mesilate 1,500 mg/day
Number of subjects: 388
Study 9130904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion
Number of subjects: 100
Study 9130904 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 100
Study 8195331 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid (20% v/v)
Number of subjects: 0
Study 8195331 — intervention group
Group type: COMPARATOR
Intervention: Progesterone (1 mmol/l)
Number of subjects: 0
Study 3539980 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 7
Study 3539980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene administration
Number of subjects: 7
Study 3539980 — intervention group
Group type: COMPARATOR
Intervention: Normal weight control subjects
Number of subjects: 7
Study 29625873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of the lower uterine segment (LUS) thickness with a threshold value of 3.5mm.
Number of subjects: 0
Study 29625873 — intervention group
Group type: COMPARATOR
Intervention: Standard practice without ultrasound measurement of LUS.
Number of subjects: 0
Study 29625873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of the lower uterine segment (LUS) thickness.
Number of subjects: 0
Study 28442422 — intervention group
Group type: EXPERIMENTAL
Intervention: 1Hz rTMS of the left TPJ
Number of subjects: 24
Study 28442422 — intervention group
Group type: EXPERIMENTAL
Intervention: 1Hz rTMS of the bilateral TPJ
Number of subjects: 24
Study 28442422 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 26450586 — intervention group
Group type: EXPERIMENTAL
Intervention: REFOCUS intervention, which includes recovery-promoting relationships and working practices, specific details on dosage and duration not available.
Number of subjects: 0
Study 23995537 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC1-MB (molecular beacon targeting myosin heavy chain 6/7 mRNA)
Number of subjects: 0
Study 23995537 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC1-MB
Number of subjects: 0
Study 23995537 — intervention group
Group type: EXPERIMENTAL
Intervention: MB-based purified cardiomyocytes
Number of subjects: 0
Study 21495077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing guideline intervention (increased individualized pleasant activities and decreased unpleasant events)
Number of subjects: 97
Study 21495077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing guideline intervention
Number of subjects: 97
Study 21495077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study 18451674 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Kt/V to 1.40 in the HEMO study
Number of subjects: 0
Study 18451674 — intervention group
Group type: EXPERIMENTAL
Intervention: Kt/V >1.0
Number of subjects: 0
Study 18451674 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment time (t) in NCDS
Number of subjects: 0
Study 18451674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose targeting observational studies (OS)
Number of subjects: 0
Study 16221942 — intervention group
Group type: EXPERIMENTAL
Intervention: KnowledgeLink (infobutton application linked to Micromedex)
Number of subjects: 359
Study 16221942 — intervention group
Group type: EXPERIMENTAL
Intervention: KnowledgeLink (infobutton application linked to SkolarMD)
Number of subjects: 359
Study 14732787 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walking Test (SWT)
Number of subjects: 18
Study 14732787 — intervention group
Group type: COMPARATOR
Intervention: 6-Minute Walking Test (6MWT)
Number of subjects: 18
Study 11088036 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (15 mg/kg single dose)
Number of subjects: 3027
Study 11088036 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g initial dose, followed by 1 g every 8 hours for 6 doses over 2 days)
Number of subjects: 3027
Study 11088036 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 3027
Study 11088036 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 3027
Study 9161110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 0
Study 9161110 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric methods for sample size calculations and analysis
Number of subjects: 0
Study 8270290 — intervention group
Group type: EXPERIMENTAL
Intervention: Kamalahar 500 mg three times a day for 15 days
Number of subjects: 52
Study 8270290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8270290 — intervention group
Group type: EXPERIMENTAL
Intervention: Kamalahar 500 mg
Number of subjects: 52
Study 3304401 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 35
Study 3304401 — intervention group
Group type: EXPERIMENTAL
Intervention: mefenamic acid
Number of subjects: 35
Study 29024542 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib tablet, 200 mg
Number of subjects: 0
Study 29024542 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib tablet with low-fat meal
Number of subjects: 0
Study 29024542 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib tablet with high-fat meal
Number of subjects: 0
Study 29024542 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib tablet with omeprazole
Number of subjects: 0
Study 27552173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 250
Study 27552173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 24847894 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan
Number of subjects: 113
Study 24847894 — intervention group
Group type: COMPARATOR
Intervention: Sodium hypochlorite
Number of subjects: 113
Study 22079088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg
Number of subjects: 98
Study 22079088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 50 mg
Number of subjects: 98
Study 22079088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 22079088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 50 or 100 mg
Number of subjects: 98
Study 18973957 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 98
Study 18296124 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day (n=84)
Number of subjects: 168
Study 18296124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=77)
Number of subjects: 168
Study 18296124 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (n=84)
Number of subjects: 168
Study 16152825 — intervention group
Group type: EXPERIMENTAL
Intervention: kurarinone combined with interferon alpha-1b (IFNalpha-1b)
Number of subjects: 146
Study 16152825 — intervention group
Group type: COMPARATOR
Intervention: interferon alpha-1b (IFNalpha-1b)
Number of subjects: 146
Study 16152825 — intervention group
Group type: COMPARATOR
Intervention: kurarinone (KR)
Number of subjects: 146
Study 16152825 — intervention group
Group type: COMPARATOR
Intervention: none (Control Group D)
Number of subjects: 146
Study 11343248 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA
Number of subjects: 10
Study 11343248 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA
Number of subjects: 10
Study 9832099 — intervention group
Group type: EXPERIMENTAL
Intervention: Color kinesis imaging in the TOF group
Number of subjects: 19
Study 8137492 — intervention group
Group type: EXPERIMENTAL
Intervention: FARM (epirubicin hydrochloride)
Number of subjects: 77
Study 8137492 — intervention group
Group type: COMPARATOR
Intervention: ADR (doxorubicin hydrochloride)
Number of subjects: 77
Study 2781858 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rabies vaccine with aluminium hydroxide-adsorbed tetanus toxoid on days 0 and 21
Number of subjects: 0
Study 2781858 — intervention group
Group type: COMPARATOR
Intervention: 2-1-1 regimen of PVRV alone
Number of subjects: 0
Study 2781858 — intervention group
Group type: COMPARATOR
Intervention: Aluminium-free tetanus toxoid
Number of subjects: 0
Study 2781858 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rabies vaccine with aluminium hydroxide-adsorbed tetanus toxoid
Number of subjects: 0
Study 1109698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes covered in the recovery room only (Group 2)
Number of subjects: 150
Study 1109698 — intervention group
Group type: COMPARATOR
Intervention: Eyes uncovered (Control Group 3)
Number of subjects: 150
Study 1109698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes covered in the operating room and recovery room (Group 1)
Number of subjects: 150
Study 7358496 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 25
Study 7358496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25